Qureight Appoints Board to Advance AI Imaging for Pulmonary Hypertension Trials

What Is Qureight and Why Does It Matter in Pulmonary Hypertension Research?

Qureight, a Cambridge-based imaging contract research organisation (CRO), has established a Scientific Advisory Board (SAB) dedicated to pulmonary hypertension (PH). The seven-member board will provide strategic and scientific input into the development of Qureight's deep learning imaging models, which are designed to generate precision endpoints for use in PH clinical trials.

The company operates as an end-to-end imaging solution provider for lung and heart disease, producing regulatory-grade data outputs intended to support therapeutic approval pathways in a disease area with significant unmet clinical need.

The Challenge of Monitoring Pulmonary Hypertension

Pulmonary hypertension encompasses several serious conditions characterised by elevated pressure in the pulmonary circulation. Diagnosis and monitoring currently rely heavily on invasive right heart catheterisation, which carries procedural burden and limits the frequency with which disease progression or treatment response can be assessed.

Non-invasive imaging-derived endpoints have been identified as a priority by clinical trialists seeking to reduce reliance on catheterisation while improving the sensitivity and reproducibility of outcome measures in interventional studies. For sponsors running trials in rare pulmonary vascular diseases, reproducible imaging endpoints could reduce screen failure rates, improve patient stratification, and provide earlier signals of treatment effect compared with traditional haemodynamic measures.

How Qureight's AI Imaging Models Work

Qureight's approach applies deep learning models to imaging data to generate quantitative markers that can serve as surrogate or supporting endpoints in trials evaluating novel PH therapeutics. The newly formed SAB will inform model development, validate clinical assumptions, and advise on regulatory strategy as the company expands its presence in the PH trial space.

The platform aims to provide a reliable, non-invasive alternative to catheterisation-based monitoring, supporting both patient safety and trial efficiency in a space where imaging-based endpoints are increasingly sought by regulators and sponsors alike.

Who Is on Qureight's Pulmonary Hypertension Scientific Advisory Board?

The board draws on expertise from leading clinical and research centres across Europe and the United States, spanning pulmonary vascular medicine, rare lung disease, and clinical trial design.

Marc Humbert (University Paris-Saclay / AP-HP) is Dean of the Faculty of Medicine at the University Paris-Saclay and Director of the French Pulmonary Hypertension Reference Centre. He has built one of the largest PH patient registries globally and devoted his career to deciphering the mechanisms of pulmonary arterial hypertension.

Steven Nathan (Inova Fairfax Hospital / Virginia Commonwealth University) is Director of the Advanced Lung Disease and Lung Transplant Program at Inova Fairfax Hospital and a former Chair of the FDA Anesthesiology and Respiratory Therapy Devices Panel. He brings substantial regulatory experience from advisory roles with the US Food and Drug Administration and steering committee involvement in PH and idiopathic pulmonary fibrosis trials.

Oksana Shlobin (Inova Fairfax Hospital / Georgetown University) is Medical Director of the Inova Pulmonary Hypertension Program and Associate Professor at Georgetown University School of Medicine, with a focus on clinical programme development and outreach in advanced lung disease.

Vincent Cottin (Louis Pradel Hospital / Claude Bernard University Lyon 1) is Professor of Respiratory Medicine and coordinator of the National Reference Centre for Rare Pulmonary Diseases, a centre recognised within the European Reference Center Network for interstitial lung diseases. He brings expertise in rare lung disease and serves on the steering committees of numerous international clinical trials.

Ardeschir Ghofrani (University Hospital Giessen and Marburg / Imperial College London) is Deputy Director and Chair of Pulmonary Vascular Medicine at the University Hospital Giessen and Marburg, a Visiting Professor at Imperial College London, and a founding member of the Pulmonary Vascular Research Institute.

Joanna Pepke-Zaba (Royal Papworth Hospital / University of Cambridge) is Consultant Chest Physician at Royal Papworth Hospital in Cambridge and Affiliated Associate Professor at the University of Cambridge. She was instrumental in establishing the National Chronic Thromboembolic PH programme in the UK, with research concentrated on chronic thromboembolic PH and idiopathic PAH.

Luke Howard (Imperial College Healthcare NHS Trust / Imperial College London) is Consultant Pulmonologist and Lead Clinician in Cardiopulmonary Medicine at Imperial College Healthcare NHS Trust and Professor of Practice at the National Heart and Lung Institute. He specialises in pulmonary vascular disease, pulmonary embolism, and exercise physiology.

What This Means for the Future of Pulmonary Hypertension Clinical Trials

The formation of a dedicated PH advisory board reflects growing interest across the clinical trials sector in validated, non-invasive imaging biomarkers as both operational and regulatory tools. As the field moves toward more patient-friendly trial designs, AI-derived imaging endpoints represent a potentially significant advance in how disease severity is measured and treatment response is tracked over time.

Qureight has not disclosed details of specific ongoing or planned trials it is supporting in the PH indication.